Bharat Biotech Dossier Under Review For Covaxin Emergency Us
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Officials of the World Health Organisation (WHO) had a meeting with those of Bharat Biotech and the Hyderabad-based vaccine maker's dossier for Emergency Use Listing (EUL) of Covaxin is under review by the technical experts for consideration, Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia said on Monday.

India has been offered 7.5 million doses of Moderna vaccine through WHO's COVID-19 Vaccines Global Access (COVAX) program. The WHO Regional Director said, "Pfizer, AstraZeneca, Moderna, Johnson and Johnson, Sinovac and Sinopharm have been granted EUL by the WHO for COVXIN" Dr Singh also informed that an expression of interest for EUL has been made to WHO by Bharat Biotech.

Cautioning about the possibility of the Delta variant of coronavirus becoming the most dominant COVID strain, Dr Singh said, "Delta variant has spread to over 100 countries, the way its spreading is likely to soon become the most dominant COVID strain globally."Among all variants of concern, Delta spreads most rapidly. The rapid spread means more cases, leading to more pressure on health systems and more deaths, she said.

Dr Singh urged people to act 'urgently' to contain the spread of the COVID-19 virus and aggressively scale up vaccination especially of the vulnerable population for containment of the possible third wave. Dr Singh also noted that cases are on a decline in India, Nepal, and Maldives. However, the situation continues to be a concern, she said.